Answers are grounded in this paper and cite their sources.
The hemophilias are a group of severe bleeding disorders resulting from the lack of functional blood coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Factor IX, when activated, catalyzes the conversion of factor X to its activated form, and activated factor VIII serves as a cofactor in this reaction. Clinically the disorders are indistinguishable, and they were not distinguished in the laboratory until the 1950s, when two research teams independently demonstrated that plasma from one group of patients could correct the clotting defect of the other group (1, 2). Clinically the disease is characterized by frequent spontaneous bleeds into joints and soft tissues, with the potential to result in a chronic and debilitating arthropathy. More serious complications, and death, can result from bleeding into other critical closed spaces, such as the intracranial or the retroperitoneal space. The disease is classified as severe, moderate, or mild, based on circulating-factor levels, with severe defined as <1% of normal activity, moderate as 1–5%, and mild as 5–30%.
No takes yet. Share an insight, caveat, or question.
Kay et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: